The Tata Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR test, powered by CSIR-Institute of Genomics and Integrative Biology (IGIB) FELUDA has received regulatory approvals from the Drug Controller General of India for commercial launch.
As per the Indian Council of Medical Research (ICMR) guidelines, the test has met high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting the Novel Corona virus. This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus. CRISPR is a genome editing technology to diagnosing diseases.
The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19. This marks a significant achievement for the Indian scientific community, moving from Research and Development to a high-accuracy, scalable and reliable test in less than 100 days.
The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment and better ease of use. Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future.
The effort is the result of a fruitful collaboration between the scientific community and industry. The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up COVID-19 testing quickly and economically, with a Made in India product that is safe, reliable, affordable, and accessible.